TY - JOUR T1 - Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 79 LP - 81 DO - 10.3899/jrheum.150643 VL - 93 AU - Fabiola Atzeni AU - Luisa Costa AU - Francesco Caso AU - Raffaele Scarpa AU - Piercarlo Sarzi-Puttini Y1 - 2015/11/01 UR - http://www.jrheum.org/content/93/79.abstract N2 - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. ER -